Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Oct 31, 2020
Date Accepted: Feb 13, 2021
Date Submitted to PubMed: Mar 19, 2021

The final, peer-reviewed published version of this preprint can be found here:

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices

Rafiei R, Williams C, Jiang J, Aungst TD, Durrer M, Tran D, Howald R

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices

JMIR Mhealth Uhealth 2021;9(3):e25406

DOI: 10.2196/25406

PMID: 33621188

PMCID: 8088878

Digital Health Integration Assessment and Maturity of U.S. Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Auto Injectable Devices

  • Ramin Rafiei; 
  • Chelsea Williams; 
  • Jeannette Jiang; 
  • Timothy Dy Aungst; 
  • Matthias Durrer; 
  • Dao Tran; 
  • Ralph Howald

ABSTRACT

Auto injectable devices continue to provide real-life benefits for patients with chronic conditions since their widespread adoption 30 years ago with the rise of macromolecules. Nonetheless, issues surrounding adherence, patient administration techniques, disease self-management, and data outcomes at scale persist despite product design innovation and are the next areas to be addressed through digital health. There is now an opportunity to create a value proposition for next generation auto injectable devices to power the delivery of precision care at home and achieve the full potential of biologics. Success will largely be dependent on biopharma’s digital health maturity to implement this framework. This viewpoint measures the digital health maturity of the top 15 biopharmaceutical companies in the US biologics autoinjector market and establishes the framework for next generation auto injectables powering home-based precision care.


 Citation

Please cite as:

Rafiei R, Williams C, Jiang J, Aungst TD, Durrer M, Tran D, Howald R

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices

JMIR Mhealth Uhealth 2021;9(3):e25406

DOI: 10.2196/25406

PMID: 33621188

PMCID: 8088878

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.